Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
IntroductionScarce real-life data exists for COVID-19 management in hematologic disease (HD) patients in the Omicron era.PurposeTo assess the current clinical management and outcome of SARS-CoV-2 infection diagnosed, identify the risk factors for severe outcomes according to the HD characteristics a...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2024-06-01
|
| Ráidu: | Frontiers in Oncology |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1389345/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
